WASHINGTON — THE Supreme Court’s unanimous ruling last Thursday, barring patents on human genes, was a wise and balanced decision that clears away a major barrier to innovation in the areas of biotechnology, drug development and medical diagnostics. But the decision is just a first step toward finding the right balance between protecting legitimate intellectual property and securing an open future for personalized medicine.